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Abstract
Background: Early infancy is a high-risk period for severe acute respiratory infection (ARI), particularly in low-income
countries with resource-limited health systems. Lower respiratory tract infection (LRTI) is commonly preceded by upper
respiratory infection (URTI), and often caused by respiratory syncytial virus (RSV), influenza and other common
community-acquired viral pathogens. Vitamin D status is a candidate modifiable early-life determinant of the host
antiviral immune response and thus may influence the risk of ARI-associated morbidity in high-risk populations.
Methods/Design: In the Maternal Vitamin D for Infant Growth (MDIG) study in Dhaka, Bangladesh (NCT01924013),
1300 pregnant women are randomized to one of five groups: placebo, 4200 IU/week, 16,800 IU/week, or 28,000 IU/
week from 2nd trimester to delivery plus placebo from 0–6 months postpartum; or, 28,000 IU/week prenatal and until
6-months postpartum. In the Maternal Vitamin D for ARI in Infancy (MDARI) sub-study nested within the MDIG trial,
trained personnel conduct weekly postnatal home visits to inquire about ARI symptoms and conduct a standardized
clinical assessment. Supplementary home visits between surveillance visits are conducted when caregivers make
phone notifications of new infant symptoms. Mid-turbinate nasal swab samples are obtained from infants who meet
standardized clinical ARI criteria. Specimens are tested by polymerase chain reaction (PCR) for 8 viruses (influenza A/B,
parainfluenza 1/2/3, RSV, adenovirus, and human metapneumovirus), and nasal carriage density of Streptococcus
pneumoniae. The primary outcome is the incidence rate of microbiologically-positive viral ARI, using incidence rate
ratios to estimate between-group differences. We hypothesize that among infants 0–6 months of age, the incidence of
microbiologically-confirmed viral ARI will be significantly lower in infants whose mothers received high-dose prenatal/
postpartum vitamin D supplements versus placebo. Secondary outcomes include incidence of ARI associated with
specific pathogens (influenza A or B, RSV), clinical ARI, and density of pneumococcal carriage.
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Discussion: If shown to reduce the risk of viral ARI in infancy, integration of maternal prenatal/postpartum vitamin D
supplementation into antenatal care programs in South Asia may be a feasible primary preventive strategy to reduce
the burden of ARI-associated morbidity and mortality in young infants.
Trial registration: NCT02388516, registered March 9, 2015.
Keywords: Vitamin D, Pregnancy, Infant, Acute respiratory infection, Pneumonia, Influenza, Respiratory syncytial virus,
Streptococcus pneumoniae, Bangladesh
Background
Early infancy is a high-risk period for severe acute re-
spiratory infection (ARI), particularly in low-income
countries with resource-limited health systems. Lower
respiratory tract infection (LRTI) accounts for more
deaths among children under the age of 5 in the world
than any other single disease [1]. Notably, the clinical
course of a LRTI often starts with an upper respiratory
tract infection (URTI) suggesting an important role of
URTI in the pathogenesis of more severe and life-
threatening LRTI. Respiratory syncytial virus (RSV) and
influenza are common viral causes of both URTI and
LRTI in young children. The treatment of RSV and in-
fluenza along with other viral infections remains unsatis-
factory and primary prevention remains a key strategy in
reducing the burden of these infections.
Vitamin D has been linked to the risk of respiratory
infections such as pneumonia, tuberculosis and bron-
chiolitis, suggesting it may be a potentially modifiable
determinant of the host immune response. It has been
postulated that lower vitamin D levels may explain the
seasonal variation in influenza and studies have shown
that children with rickets are at increased risk of lower
respiratory tract disease or pneumonia [2–4]. Higher
rates of invasive pneumococcal disease have been associ-
ated with decreased ultraviolet light exposure through
the postulated mechanism of lower vitamin D levels [5].
Vitamin D has been shown to modulate the innate im-
mune response in lung epithelial cells [6, 7], and anti-
microbial peptides induced by vitamin D may have
antiviral effects based on observed activity against herpes
simplex virus-1 (HSV-1) [8], adenovirus [9], human im-
munodeficiency virus (HIV) [10] and vaccinia [11]. In
RSV-infected human airway epithelial cells, vitamin D
induces Iκβα, an NF-κB inhibitor, in airway epithelium
and decreases RSV induction of inflammatory genes [7].
Several observational studies have evaluated the associ-
ation of serum 25-hydroxyvitamin D (25 (OH) D) concen-
tration with incidence or severity of respiratory tract
infections. Studies in adults have shown an association be-
tween lower 25 (OH) D concentrations and increased
URTI (self-reported) [12–14] and absence from work due
to respiratory symptoms [12, 15]. Pediatric studies have
focused predominantly on LRTI (chest X-ray confirmed
pneumonia or bronchiolitis) [16–20]. These studies
have shown an association between low serum 25
(OH) D levels and risk of LRTI in children in India
[16], Bangladesh [19] and Turkey [17]. More recently,
a study in Hutterite communities in Canada found an
association between serum 25 (OH) D level and la-
boratory confirmed URTI [21].
Despite these suggestive results from observational
studies, there have been few prospective randomized
controlled trials examining the impact of vitamin D sup-
plementation on risk of ARI in children. In a trial in
Japan, school children randomized to 1200 IU/day of
vitamin D compared to placebo had a significantly de-
creased risk of developing laboratory-proven influenza A
(RR 0.58, 95 % CI 0.34, 0.99) but not influenza B (RR
1.39, 95 % CI 0.90-2.15) [22]. Similarly, a decrease in
parent-reported ARI was noted in children in Mongolia
given vitamin D-fortified milk (300 IU of vitamin D3)
[23], in a setting in which children had very low baseline
serum 25 (OH) D levels. However, a trial in Afghanistan
involving over 3000 children randomized to receive
quarterly doses of 100,000 IU of vitamin D or placebo
found no difference in the incidence of pneumonia [24].
The first randomized trial of prenatal vitamin D supple-
mentation on childhood wheeze was recently published
[25]. In this study, pregnant women in London, England
were randomized at 27 weeks gestation to receive either
no vitamin D, 800 IU ergocalciferol daily until delivery, or
a single bolus of 200,000 IU cholecalciferol. This study
found no difference in ‘wheeze ever’ between groups nor
any difference in prevalence in LRTIs after adjusting for
multiple testing. However, the researchers identified mul-
tiple limitations in their study including lack of blinding of
participants and subjective outcomes, small sample size
and limited statistical power, and dosages of vitamin D
that lead to only 13 % of the daily group and 3 % of the
bolus group having cord serum 25 (OH) D levels consid-
ered to be in a sufficient range.
The Maternal Vitamin D for ARI (MDARI) study ad-
dresses important gaps in the vitamin D and respiratory
tract infection literature. First, there have been no studies
examining the effect of prenatal vitamin D supplementa-
tion on a primary outcome of laboratory-confirmed viral
respiratory infections in the first 6 months of life, a high-
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risk period for both vitamin D deficiency and respiratory
tract infections. Second, the role of prenatal vitamin D as
a determinant of susceptibility to specific viral infections
has not been examined. Third, there have been no studies
assessing the association between vitamin D supplementa-
tion and quantitative nasal carriage of Streptococcus pneu-
moniae (pneumococcus), the most important cause of
bacterial LRTI in young children worldwide.
In South Asia, biochemical vitamin D deficiency is
common among women and young infants [26]. Our
study in Dhaka is being conducted in a population
known to have a high prevalence of vitamin D deficiency
as well as high incidence of early infant respiratory infec-
tion morbidity and mortality [27–29].
This study is integrated into a randomized clinical trial
of maternal vitamin D supplementation for which the
primary outcome is length at one year of age (Maternal
Vitamin D for Infant Growth (MDIG) Trial, Clinicaltrial-
s.org identifier NCT01924013), currently underway in
Dhaka, Bangladesh and funded by the Bill and Melinda
Gates Foundation (Achieving Health Growth Platform
Grant OPP1066764) [30]. We hypothesize that among
infants 0–6 months, the incidence of microbiologically
confirmed ARI will be significantly lower in infants of
mothers who received a relatively high dose of vitamin D
(28,000 IU/week) during pregnancy plus continued post-
partum supplementation (to 6 months postpartum) com-
pared to mothers who received placebo throughout the
prenatal and postpartum periods. If a significantly de-
creased incidence of microbiologically confirmed ARI is
found, we will further assess for effect of lower doses of
prenatal maternal vitamin D supplementation. We aim to
quantify the effect of maternal vitamin D supplementation
on the relative incidence of, a) microbiologically con-
firmed ARI (primary outcome); b) ARI due to influenza




The MDIG trial is a randomized placebo-controlled dose-
ranging trial of maternal vitamin D supplementation during
pregnancy and lactation to improve infant linear growth in
Dhaka, Bangladesh. The detailed methods of the MDIG
trial are published elsewhere [30]. The research group is
primarily a collaboration between icddr,b (International
Centre for Diarrhoeal Disease Research, Bangladesh) and
the Hospital for Sick Children (Toronto, Canada). Pregnant
women were enrolled beginning on March 18, 2014
and enrolment is expected to proceed until August
2015. Enrolment of infants in the MDARI sub-study
began on December 2, 2014 and will continue until
all infants born in the MDIG trial have been offered
enrolment (expected completion by January 2016).
Setting
The single-site trial is being conducted in Dhaka. Microbi-
ologic testing is being conducted at the Virology Labora-
tory of icddr,b. Enrolment and clinical activities of the
MDIG trial is based at the Maternal and Child Health
Training Institute (MCHTI), commonly known as
Azimpur Maternity Center, a government facility that pro-
vides low-cost health care to pregnant women and chil-
dren in its referral area in central Dhaka. Full details
regarding the trial site geography and population are pro-
vided in the MDIG trial methods paper [30].
Participants
All infants born to women enrolled in the MDIG trial
are eligible for the MDARI sub-study. Maternal inclu-
sion criteria for the MDIG trial include being at least
18 years of age, 17 to 24 completed weeks of gestation
based on a combination of recalled last menstrual period
(LMP) and ultrasound, according to a conventional algo-
rithm (per the Society of Obstetricians and Gynecolo-
gists of Canada), and intention to permanently reside in
the trial catchment area for the duration of the study.
Participants are informed of the ARI sub-study by a re-
search study physician at a clinical visit after enrolment
in the main trial. We obtain separate written informed
consent for participation in the MDARI sub-study. We
aim to enroll at the 30 week gestational age study visit,
however, given that the MDIG trial began before
MDARI, we also enroll at prenatal visits after 30 weeks,
at the time of delivery, and during home visits to infants
who were younger than 6 months of age at the time
MDARI launched. Participants are free to withdraw from
MDARI while remaining in MDIG but withdrawal from
MDIG results in automatic withdrawal from MDARI.
Interventions and randomization
A full description of the intervention groups along with the
rationale for choice of vitamin D dosages may be found in
the methods paper describing the MDIG trial [30]. Three
intervention groups are receiving weekly prenatal vitamin
D supplementation of 4200 IU/week, 16,800 IU/week, or
28,000 IU/week respectively given as a single weekly dose
beginning in the 2nd trimester of pregnancy. These three
groups all receive placebo post-partum. A fourth group is
receiving 28,000 IU/week during pregnancy and will con-
tinue with this level of supplementation until 26 weeks
postpartum. A fifth control group is receiving placebo both
pre and post-partum (Fig. 1). Infant dietary patterns are
assessed at weekly visits to assess breastfeeding patterns
and timing of introduction and frequency of consumption
of specific complementary foods.
Most infants born to mothers in the placebo and
4200 IU/week groups are not expected to demonstrate
neonatal 25 (OH) D ≥ 50 nmol/L, whereas most infants
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in the 16,000 IU/week and the 28,000 IU/week groups
(including participants that will continue to receive
28,000 IU/week post-delivery) are expected to have 25
(OH) D ≥ 50 nmol/L in early infancy. Although the clin-
ical significance of the 50 nmol/L threshold in early in-
fancy remains to be established, this is the cut-off
corresponding to the recommended dietary allowance
established by the Institute of Medicine in 2011 for all
age groups [31]. To promote optimal regimen adher-
ence, doses are delivered weekly (e.g., 28,000 IU per
week to deliver the approximate equivalent of 4000 IU/
day) and supplementation is directly observed by study
personnel whenever feasible.
Design
This is a prospective cohort study nested within a ran-
domized, placebo-controlled trial with concealment of
allocation and blinding throughout intervention and
analysis. In the main MDIG trial, a total of 1,300 preg-
nant women will be randomized, targeting 260 women
in each group (Fig. 1). The allocation sequence was
generated by the trial statistician using a computer-
generated random number sequence, according to a
simple randomization scheme. Participants, investiga-
tors, field personnel, study lab staff and data analysts are
blinded to vitamin D or placebo group allocation. Con-
sent to the MDIG trial is necessary to be eligible for the
MDARI study; however, participants in MDIG may
choose to decline participation in MDARI.
Study outcomes
The primary study outcome is microbiologically con-
firmed ARI. Main secondary outcomes include ARI with
microbiologic confirmation of influenza A, influenza B,
or RSV; clinical ARI; and quantitative nasal S. pneumo-
niae carriage density. The clinical case definitions for
ARI, URTI, and LRTI are shown in Table 1. When an in-
fant meets any of the sets of criteria for clinical URTI or
LRTI, nasal swab collection is indicated. All nasal swabs
are optimally collected within 24 h of notification, how-
ever a nasal swab may still be collected within 7 days fol-
lowing clinical case ascertainment (or within 7 days of
hospital discharge) [32–34]. No participant has more
than 1 nasal swab collected within 7 days, regardless of
the severity of the illness. Swabs are tested by polymer-
ase chain reaction (PCR) for a panel of respiratory vi-
ruses consisting of influenza A, influenza B, RSV,
parainfluenza 1, 2, and 3, adenovirus, and human metap-
neumovirus. Swabs are also be tested for quantitative S.
pneumoniae carriage density. Full details of microbio-
logic testing are presented below. To be considered an
incident case, there must be either a preceding surveil-
lance week in which a clinical case definition was not
met or a worsening of a case from URTI to LRTI or
Fig. 1 Maternal Vitamin D Acute Respiratory Infection (MDARI) trial flow diagram
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from LRTI to hospitalized LRTI. To avoid including
common neonatal problems that may present similarly
to ARI (e.g., transient tachypnea of the newborn), case
definitions cannot be met in the first 7 days of life.
Surveillance of acute respiratory infections
Active and passive surveillance mechanisms are being uti-
lized to prospectively identify new cases of clinical ARI
among infants during the 0–6 month postnatal period.
Active surveillance visits are attempted on a weekly
basis during the first 6 months of life and are imple-
mented through the existing design and infrastructure of
the MDIG study [30]; the majority of these visits occur
in participants’ homes. At each surveillance-visit, study
field personnel trained according to the Integrated Man-
agement of Childhood Illness (IMCI) program (WHO/
UNICEF) [35] administer a standardized questionnaire
and conduct an infant-clinical examination. The ques-
tionnaire and physical exam have been designed to
optimize the collection of maternal-reported and CHW-
observed infant morbidity data. Information pertaining
to the following ARI-related symptoms is collected: 1)
maternal-reported cough, rhinorrhea (i.e., runny nose),
nasal congestion (i.e., stuffy nose), difficulty breathing,
and infant-hospitalizations related to a breathing prob-
lem or chest infection (e.g., pneumonia); and, 2) CHW-
observed axillary temperature ≥ 37.5 °C (confirmed with
a second measurement), lower chest wall indrawing, and
elevated respiratory rate (≥60 breaths per minutes for in-
fants up to 59 days of age or ≥ 50 breaths per minute for
infants 60 days of age or older). The routine collection
of these data facilitates the weekly identification of new,
worsened, or persistent cases of ARI. The identification
of any one symptom indicative of a possible ARI during
weekly surveillance visits triggers a field worker to notify
the Nasal Swab Dispatcher (MDARI study physician).
The Nasal Swab Dispatcher assesses the information to
determine whether the clinical case definition of URTI
and/or LRTI has been met, and whether a nasal swab
specimen should be collected (i.e., no nasal swab col-
lected within past 7 days, at least one study visit at
which URTI and LRTI were absent or if not, the ARI
clinical case definition has worsened since the last nasal
swab was collected).
To identify cases of ARI that arise between scheduled
visits, a passive surveillance system has been imple-
mented that relies on the report of ARI symptoms by
parents/guardians. At enrolment, mothers are instructed
to notify the Nasal Swab Dispatcher by telephone if their
infant develops any one of the following symptoms:
runny nose, nasal congestion, cough, difficulty breathing,
feels hot to the touch, or the infant has been hospital-
ized. An incentive of approximately $0.25 USD of cell
phone credit is provided to families who report an ARI-
related symptom. The Nasal Swab Dispatcher assesses
the information to evaluate whether the ARI clinical case
definition has possibly been met (at least one of cough,
runny nose, congestion, hot to the touch, difficulty
breathing, or ARI-related hospitalization) and whether
collection of a nasal swab is possible (i.e., no nasal swab
collected within past 7 days, at least one study visit at
which URTI and LRTI were absent or if not, a reassess-
ment must be conducted to determine whether the ARI
clinical case definition has worsened since the last nasal
swab was collected). Caregiver-reported ARI symptoms
are verified in-person through a short questionnaire and
infant-clinical examination conducted by a trained nasal
swab collector; the clinical assessment is typically per-
formed in the participants’ home. A nasal swab speci-
men will only be collected if the clinical criteria for
Table 1 Study outcome definitions
Acute Respiratory Infection (ARI) Any upper respiratory tract infection or lower respiratory tract infection as defined below
Clinical Upper Respiratory Tract Infection (URTI) A new-onset illness consisting of at least two of the following clinical criteria at any time
during a surveillance week:
• Caregiver-reported cough;
• Caregiver-reported rhinorrhea;
• Caregiver-reported nasal congestion;
• Measured temperature ≥37.5 °C (axillary)
confirmed with 2nd measurement
Clinical Lower Respiratory Tract Infection (LRTI) • Caregiver-reported cough AND/OR difficulty breathing during a surveillance week
AND
• Observed elevated respiratory rate (60 breaths per minute or greater for infant up to
59 days of age, or 50 breaths per minute or greater for infant 60 days of age or older)
and/or lower chest wall in-drawing
OR
• Hospitalization with physician diagnosis of pneumonia or bronchiolitis
Microbiologically Confirmed URTI URTI that tests positive for at least one of influenza A, influenza B, respiratory syncytial
virus, parainfluenza 1, 2, and 3, adenovirus, or human metapneumovirus
Microbiologically Confirmed LRTI LRTI that tests positive for at least one of influenza A, influenza B, respiratory syncytial
virus, parainfluenza 1, 2, and 3, adenovirus, or human metapneumovirus
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URTI and/or LRTI are verified. All MDIG-study physicians
have been trained to notify the Nasal Swab Dispatcher if
any symptom indicative of a possible ARI is detected dur-
ing an interaction with an enrolled infant. The Nasal Swab
Dispatcher assesses the physician-reported information to
determine whether the clinical case definition of an ARI
has been met. If an infant is hospitalized with a physician
diagnosis of pneumonia or bronchiolitis, the nasal swab
collector collects a swab during the hospitalization, or if
this is not possible, within 7 days of discharge.
Pulse oximetry
Measures of infant peripheral oxygen saturation (SpO2)
are collected for every infant that meets or possibly meets
the clinical case definition of an ARI. SpO2 is measured
with a hand-held pulse oximeter device (Rad-5v with
LNCS Y-shaped sensor and LNC-04 connector cable,
Masimo California, USA). A threshold of SpO2 < 90 % is
used to guide the referral of infants to hospital for further
assessment.
Microbiologic specimen collection
Among infants meeting the definition for clinical ARI as
described above, the study worker obtains parental con-
sent to perform nasal swabbing on the infant using sterile
flocked swabs (Copan Diagnostics, Inc., model number
56780CS01) to obtain nasal epithelial cells for laboratory
analysis. Nasal flocked swabs, which are inserted more
proximately in the nares than a traditional nasopharyngeal
swab, are better tolerated by the child, easier to perform
for the health care worker, and reliably provide adequate
sample for molecular testing for respiratory viruses
[36–38]. Testing is performed by swabbing the nares
to the level of the nasal turbinate to obtain a sample of ex-
foliated cells from the mucosal lining. The infant’s head is
tilted backwards to an angle of 70° and the swab is gently
inserted by the study worker horizontally into the nasal
passage approximately one-half the distance from the nos-
tril to the earlobe or until the stopper meets the infant’s
nose or until resistance is met at the level of the turbinate.
The swab is then rotated two to three times and held it
place for 5–10 s to absorb sample material. The swab is
then removed and immediately placed into a collection
vial labeled with the patient’s study number and contain-
ing 1–3 ml of universal transport medium (Copan Diag-
nostics, Inc.). The vial is placed into an insulated cold bag
and transported to a −80 °C study freezer for storage until
testing is done.
Only one nasal swab will be collected for each episode
of ARI and there will not be more than 1 swab collected
in a 1-week period. We estimate that most infants will
not receive more than about one swab per month until
they reach 6 months of age, and typically we expect an
infant to have 3–4 swabs during this period. Participant
families receive 200 taka (~$2.50 USD) for the time in-
volved in the nasal swab procedure.
Laboratory analysis
Respiratory samples are processed and analyzed in the
Virology Lab at icddr,b in Dhaka. For each nasal swab
specimen, two aliquots are prepared; one aliquot is proc-
essed for real-time assays and one aliquot is stored at
−80 °C for future reference. Total nucleic acids are ex-
tracted from sample using InviMag Pathogen Kit/KF96
(STRATEC Molecular, Berlin, Germany) to an eluate
volume of 200 μl according to the manufacturer’s in-
structions. The InviMag Pathogen Kit/ KF96 contains
the lyophilized lysis component (lysis buffer, Proteinase
K and Carrier RNA) for bacterial DNA, viral DNA and
viral RNA isolation. Lysed samples are mixed with mag-
netic beads and nucleic acids are isolated according to
the manufacturer’s instructions. All real time PCR tests
undergo a visual check; if quality of the amplification is
not good the test is repeated and/or considered negative.
A house-keeping gene, RNP, is used as an indicator of
perfect nucleic acid extraction, to check for epithelial
cells, sample quality, quality of RT-PCR, and to monitor
for PCR inhibition.
To detect and quantitate pneumococcal copy number,
quantitative real-time PCR (qPCR) assays are performed
to amplify lytA, a single-copy autolysin gene that is spe-
cific to all S. pneumoniae strains (Table 2). This method
is based on the U.S. Centers for Disease Control and
Prevention (CDC) method as described by Carvalho et
al., and adapted from the National Institute of Commu-
nicable Diseases (NICD) in South Africa. The qPCR as-
says are carried out in a final reaction volume of 25 μl,
each containing 10 μl of extracted total nucleic acid. The
lytA primers and probes are added to a final concentra-
tion of 10 μM. DNA is amplified in a ABI 7500 (Applied
Biosystem, USA) using the following cycling parameters:
95 °C for 10 min followed by 40 cycles of 95 °C for 15 s
and 60 °C for 1 min. All standards are performed in trip-
licate and a negative (no template) and positive (lytA
plasmid control) control is included in every run along
with the samples. lytA amplification data is analyzed
using 7500 software version 2.0.6 (Applied Biosystem,
USA). The baseline and threshold are manually set at
>0.05, the slope of the standard curve is between −3.1 to
−3.6 and correlation should be >0.9. The cutoff value
CT < 35 is considered as positive. A CT value of ≤38
showing appropriate amplification on visual check is also
considered a positive result.
Individual real-time one step reverse transcriptase-PCR
(qRT-PCR) assays are being used to detect influenza A
and B viruses. Primer and probe sequences were designed
on the basis of CDC recommendations (Table 2). The
qRT-PCR assays are carried out in a final reaction volume
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of 25 μl, each containing 5.0 μl of extracted nucleic acid.
The specific influenza A and B primers and probes are
added to a final concentration of 20 μM and 5.0 μM re-
spectively. The qRT-PCR reaction is carried out with any
of the following machines; ABI 7500 (Applied Biosystem,
USA), CFX-96 (Bio-Rad, USA) or LightCycler 480 (Roche,
Switzerland) using the following cycling parameters: 50 °C
for 30 min, 95 °C for 5 min, 46 cycles at 95 °C for 15 s and
55 °C for 1 min. A negative control (no template) and a
CDC provided positive control is included in every run
along with the samples. The amplification data is analyzed
using machine specific softwares. The cutoff value CT <
35 is considered positive. A CT value of ≤38 showing ap-
propriate amplification on visual check is also be consid-
ered a positive result.
Individual qRT-PCR assays for 6 viruses (adenovirus,
human metapneumovirus [HMPV], human parainfluenza
viruses 1–3 and respiratory syncytial virus [RSV]) are be-
ing carried out according to the procedure described by
Weinberg et al. [39]. Primer and probe sequences were
designed on the basis of CDC recommendations (Table 2).
All individual qRT-PCR assays are performed with any of
the following machines; ABI 7500 (Applied Biosystem,
USA), CFX-96 (Bio-Rad, USA) or LightCycler 480 (Roche,
Switzerland), using following cycling parameters; 45 °C for
10 min, 95 °C for 10 min, and 45 cycles of 95 °C for 15 s
and 55 °C for 1 min. A negative control (no template) and
CDC provided specific positive control is included in
every run along with the samples. The amplification data
is analyzed using machine specific softwares. The cutoff
Table 2 Primers and probes used in this study for qPCR reactions
Primer Name Primer/probe Sequence (5′-3′) Nucleotide Sequence 5′-3′
lytA Forward ACG CAA TCT AGC AGA TGA AGC A
Reverse TCG TGC GTT TTA ATT CCA GCT
Probe (Pb 400) 6FAM-TGC CGA AAA CGC TTG ATA CAG GGA G-MGB
InfA Forward GAC CRA TCC TGT CAC CTC TGA C
Reverse AGG GCA TTY TGG ACA AAK CGT CTA
Probe1 6FAM-TGC AGT CCT CGC TCA CTG GGC ACG-BHQ1
InfB Forward TCC TCA AYT CAC TCT TCG AGC G
Reverse CGG TGC TCT TGA CCA AAT TGG
Probe1 6FAM-CCA ATT CGA GCA GCT GAA ACT GCG GTG-BHQ1
RNP Forward AGA TTT GGA CCT GCG AGC G
Reverse GAG CGG CTG TCT CCA CAA GT
Probe1 6FAM-TTC TGA CCT GAA GGC TCT GCG CG-BHQ1
RSV Forward GGC AAA TAT GGA AAC ATA CGT GAA
Reverse TCT TTT TCT AGG ACA TTG TAY TGA ACA G
Probe1 6FAM-CTG TGT ATG TGG AGC CTT CGT GAA GCT-BHQ1
HMPV Forward CAA GTG TGA CAT TGC TGA YCT RAA
Reverse ACT GCC GCA CAA CAT TTA GRA A
Probe 1 6FAM-TGG CYG TYA GCT TCA GTC AAT TCA ACA GA-BHQ1
HPIV1 Forward ACA AGT TGT CAA YGT CTT AAT TCR TAT
Reverse TCG GCA CCT AAG TAR TTY TGA GTT
Probe 6FAM-ATA GGC CAA AGA “T”TG TTG TCG AGA CTA TTC CAA
HPIV2 Forward GCA TTT CCA ATC TAC AGG ACT ATG A
Reverse ACC TCC TGG TAT AGC AGT GAC TGA AC
Probe 6FAM-CCA TTT ACC “T”AA GTG ATG GAA TCA ATC GCA AA
HPIV3 Forward TGG YTC AAT CTC AAC AAC AAG ATT TAA G
Reverse TAC CCG AGA AAT ATT ATT TTG CC
Probe1 6FAM-CCC RTC TG“T” TGG ACC AGG GAT ATA CTA CAA A
Adeno Forward GCC CCA GTG GTC TTA CAT GCA CAT C
Reverse GCC ACG GTG GGG TTT CTA AAC TT
Probe 6FAM-TG CAC CAG ACC CGG GCT CAG GTA CTC CGA-BHQ1
Note: Quenched internally at a modified “T” residue with BHQ1 and a terminal phosphate at the 3′-end to prevent probe extension by Taq polymerase
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value CT < 35 is considered positive. A CT value of ≤38
showing appropriate amplification on visual check is also
considered a positive result.
Data management
A site supervisor reviews all forms for completeness and
protocol deviations before sending forms to the data
management center at icddr,b. Electronic (scanned) ver-
sions of all forms are also regularly saved for long-term
storage. The database was designed using SQL Server
2008 and data are entered using Visual Studio 2010. A
set of range and consistency checks are built into the
data capture system to provide immediate feedback to
data entry personnel regarding errors or inconsistent
data. Double data entry is used to further reduce the rate
of date entry errors.
Statistical analysis
Sample size and power calculations
The number of children in each of the five arms of the
MDARI study is determined by the main MDIG trial.
For MDARI analyses, we made several assumptions in-
cluding: maximum of 260 infants in each group, but
with 10 % attrition/loss prior to enrolment in MDARI;
incidence rate of microbiologically confirmed ARI in the
placebo group of 3 cases per child-year; incidence of
clinical ARI in the placebo group of 6 cases per child-
year; two-sided type 1 error rate of 0.05; power of 80 %;
and effect estimate reported as a hazard ratio (HR) (risk
in intervention group vs. placebo group).
We anticipate that the effect of maternal vitamin D
supplementation will be incremental with increasing
dose, such that the greatest effect size (vs. placebo) will
be observed in the highest dose vitamin D group with
postpartum continuation (group E in Fig. 1). Therefore,
the primary aim and power calculation are based on the
pair-wise comparison of group E vs. group A (placebo).
This will test the core mechanistic hypothesis that im-
provements in vitamin D status via maternal vitamin D
supplementation reduce the risk of ARI among infants
in Dhaka. For the primary analysis, we will use a gate-
keeper approach, whereby we will proceed to compari-
sons of shorter and/or lower dose groups (versus
placebo) only if the primary comparison of E vs. placebo
is statistically significant. For example, if E vs. placebo is
significant (p < 0.05), then we will proceed with D vs.
placebo, and so forth. This approach provides strong
control of the family-wise error rate (type I error) while
maintaining high power for the primary comparison
[40]. Our primary analysis will also estimate hazard ra-
tios and 95 % confidence intervals for each dose relative
to placebo. We thus maintain 80 % power to address the
question of whether maternal vitamin D supplementa-
tion can reduce the rate of microbiologically-confirmed
acute respiratory infections, while simultaneously being
able to address whether lower doses are also effective,
and to investigate whether a dose–response relationship
exists, thereby supporting the biological plausibility and
robustness of inferences. At the assumed baseline event
rate of 3 events per child-year, we will be able to detect
a HR of 0.74 with 80 % power, representing a 26 % re-
duction in the rate of microbiologically-confirmed ARI.
We believe that this is consistent with a minimum
clinically-relevant reduction in risk.
In secondary analyses, we will consider aggregation of
multiple vitamin D arms (e.g., group D and E), which
will have the benefit of increasing the sample size; how-
ever, for the a priori primary outcome analysis, we have
decided to retain the separation of the groups (according
to the design of the MDIG trial) to limit the possibility
of increasing a type II error if a true effect of the longer
duration or higher-dose intervention were diluted by the
lack of effect of the other group(s). Secondary analyses
will also replicate the above analyses for clinical respira-
tory infections (i.e., meets clinical definition with or
without microbiologic confirmation) and influenza or
RSV associated infections.
Analytic plans
The primary analysis will be conducted as an intention-
to-treat analysis and will include all randomized infants
who enter the postnatal follow-up period (i.e., infants
born to mothers who consent during pregnancy and in-
fants whose mothers consent postnatally). The primary
aim is based on the pair-wise comparison of high dose
group E vs. placebo. If the evidence indicates a difference
between group E vs. placebo (p < 0.05), we will proceed to
selected between-group comparisons versus placebo. As
there is expected to be some loss to follow-up (censoring),
the primary approach will employ a time-to-event (sur-
vival) analysis. Specifically, we will use the Anderson-Gill
extension of the Cox proportional hazards model to
enable the appropriate analysis of recurrent events (i.e., re-
peated episodes of infection within the same child). The
primary effect measure will be hazard ratios, which in this
context are the same as incidence rate ratios (IRRs). How-
ever, in contrast to some regression models that directly
yield IRRs (e.g., Poisson regression) the approach has the
advantage of not requiring the assumption of a constant
baseline incidence rate. The models will apply jackknife
estimators of the standard errors to account for correl-
ation within infants over time [41]. This approach has a
similar aim as generalized estimating equations or mixed
effects models to account for the non-independence of re-
peated events within the same child, without requiring us
to discard events from multiple episodes (as in, for ex-
ample, a time-to-first-event analysis). The time unit of
analysis is the study week. Following an ARI meeting
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clinical case definition, weekly active surveillance con-
tinues, however, the infant will not be considered ‘at risk’
of a new ARI until there has been one documented case
definition free study week or more than 4 study weeks
have elapsed (in cases where intervening surveillance visits
were missed).
Secondary analyses will include comparing aggregated
“high-dose” vitamin D groups (16,800 IU/week (Group C)
and 28,000 IU/week (Group D)) versus low/no vitamin D
groups (4200 IU/week (Group B) and placebo (Group A))
to optimize power for detecting smaller differences. A spe-
cific pairwise comparison between the 28,000 IU/week
prenatal + postpartum group (Group E) will be compared
to 28,000 IU/week without postpartum supplementation
(Group D) to identify the impact of continuing vitamin D
supplementation in the postpartum period.
The main secondary outcomes are confirmed infection
with influenza (A or B) or RSV, clinical ARI, URTI, and
LRTI (i.e., clinical case definition is met but without the
need for positive microbiology). The secondary analysis
will also be conducted as an intention-to-treat analysis,
will include all randomized infants, and will use inci-
dence rate ratios to quantify between group differences.
For the secondary outcomes, we will use recurrent event
models fitted through proportional hazards models for
confirmed RSV or influenza (separately by type of infec-
tion) and for clinical ARI, URTI, and LRTI (separately
by clinical category). In sensitivity analyses to test the ro-
bustness of the primary findings, we will consider adjust-
ment for baseline covariates for which distributions
differ across the intervention groups.
Given the expected non-normal distribution of the
data, S. pneumococcus density will be reported as median
values with inter-quartile range. Differences in continu-
ous variables such as density will be assessed using the
Mann–Whitney and p < 0.05 will be considered statisti-
cally significant. When assessing difference in density of
multiple groups, a Kruskall-Wallis analysis of variance
will be employed.
Discussion
The MDARI study in Dhaka, Bangladesh leverages the
infrastructure of a large randomized placebo controlled,
dose-ranging trial of maternal vitamin D supplementa-
tion during pregnancy and lactation in Bangladesh to
test the hypothesis that maternal vitamin D supplemen-
tation can decrease infant respiratory infections during
the high risk first 6 months of infancy. If shown to re-
duce the risk of ARI in infancy, integration of maternal
prenatal/postpartum vitamin D supplementation into
antenatal care programs in South Asia may be a feasible
primary preventive strategy to reduce the burden of
ARI-associated morbidity and mortality in young infants.
Trial status
Data collection is ongoing.
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